Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β<sub>2</sub> Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases-Reference-Cited by-同舟云学术

Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β₂ Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases

Published:2022-07-28 Issue:15 Volume:65 Page:10233-10250
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Carzaniga Laura¹^ORCID,Linney Ian D.²,Rizzi Andrea¹,Delcanale Maurizio¹,Schmidt Wolfgang²,Knight Christopher K.²,Pastore Fiorella³,Miglietta Daniela³,Carnini Chiara⁴,Cesari Nicola⁵,Riccardi Benedetta⁵,Mileo Valentina⁶,Venturi Luca⁶^ORCID,Moretti Elisa⁶,Blackaby Wesley P.²,Patacchini Riccardo⁴,Accetta Alessandro¹,Biagetti Matteo¹,Bassani Franco³,Tondelli Marina³,Murgo Annalisa³,Battipaglia Loredana⁷,Villetti Gino³,Puccini Paola⁵,Catinella Silvia⁶,Civelli Maurizio⁸,Rancati Fabio¹

Affiliation:

1. Chemistry Research and Drug Design Department, Chiesi Farmaceutici S.p.A, Research Center, Largo Belloli 11/a, 43122 Parma, Italy

2. Medicinal Chemistry Department, Charles River, Chesterford Research Park, Saffron Walden, CB10 1XL Essex, United Kingdom

3. Pharmacology Department, Chiesi Farmaceutici S.p.A, Research Center, Largo Belloli 11/a, 43122 Parma, Italy

4. Project Leader, Corporate Drug Development, Chiesi Farmaceutici S.p.A Research Center, Largo Belloli 11/a, 43122 Parma, Italy

5. Pharmacokinetics Biochemistry and Metabolism Department, Chiesi Farmaceutici S.p.A, Research Center, Largo Belloli 11/a, 43122 Parma, Italy

6. Analytics and Early Formulation Department, Chiesi Farmaceutici S.p.A, Research Center, Largo Belloli 11/a, 43122 Parma, Italy

7. Safety & Toxicology Department, Chiesi Farmaceutici S.p.A Research Center, Largo Belloli 11/a, 43122 Parma, Italy

8. Head of Global Research & Preclinical Development, Chiesi Farmaceutici S.p.A, Research Center, Largo Belloli 11/a, 43122 Parma, Italy

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00609

Reference28 articles.

1. Epidemiology of chronic obstructive pulmonary disease: a literature review

2. Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998–2010

3. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

4. Chronic obstructive pulmonary disease

5. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β₂ Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases;Journal of Medicinal Chemistry;2024-06-10

2. The future drug treatment of COPD;COPD in the 21st Century;2024-03-01

3. Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update;Expert Opinion on Pharmacotherapy;2023-11-15

4. Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval;Expert Opinion on Investigational Drugs;2023-06-03

5. Unbinding Kinetics of Muscarinic M3 Receptor Antagonists Explained by Metadynamics Simulations;Journal of Chemical Information and Modeling;2023-04-13